Organon Earnings Call Balances Stability With Rising Risks

Organon & Co. ((OGN)) has held its Q4 earnings call. Read on for the main highlights of the call.

Organon & Co.’s latest earnings call struck a cautious but resilient tone. Management balanced solid operational wins, such as strong biosimilars momentum, disciplined cost control and steady cash generation, against clear commercial and margin pressures. Investors heard a story of stability rather than growth, with 2026 guided essentially flat and execution risk still elevated.

Revenue, EBITDA and a “Hold the Line” Outlook

Organon reported 2025 revenue of $6.2 billion, down about 3% year over year on both a reported and constant-currency basis, with adjusted EBITDA of $1.9 billion. For 2026, management is effectively calling for a repeat performance at roughly the same revenue and EBITDA levels, signaling a focus on defending the current earnings base instead of chasing aggressive expansion.

Biosimilars: Hadlima Leads a Durable Growth Engine

Biosimilars remained a bright spot, with Hadlima growing around 61% ex-FX globally in 2025 and new denosumab launches plus the Tofidence acquisition expanding the portfolio. Management expects this segment to deliver flat to modest growth in 2026 as newer assets help offset anticipated declines in Ontruzan and Renflexis, keeping biosimilars an important growth and diversification pillar.

Vtama, Emgality and Fertility Cushion Structural Headwinds

Vtama contributed $128 million in global revenue for 2025, while Emgality and the fertility franchise delivered strong gains, with fertility up 8% ex-FX for the year. Together, these growth assets helped buffer the company from loss-of-exclusivity volume erosion and respiratory pricing pressure, highlighting the value of newer products in stabilizing the top line.

Nexplanon Label Expansion: Long-Term Opportunity, Near-Term Friction

The FDA’s approval of a supplemental application extending Nexplanon’s duration from 3 to 5 years is a strategic win that broadens the addressable market, including higher-BMI patients. The new labeling, coupled with an updated REMS program, underpins Nexplanon’s long-term potential even as the product works through near-term commercial and operational disruptions.

Cost Savings Support Margins Amid Pressure

Organon achieved more than $200 million of cost savings in 2025 against a gross target of about $275 million, reflecting aggressive expense discipline. Despite roughly 150 basis points of gross margin erosion for the year, management held adjusted EBITDA margin at about 30.7%, essentially flat with 2024, underscoring the strength of the company’s cost-control efforts.

Cash Generation, Jada Sale and Deleveraging Efforts

The company generated $960 million of free cash flow in 2025, broadly in line with the prior year, and completed the divestiture of the Jada system for roughly $390 million of net proceeds in early 2026. Organon also retired about $530 million of debt in 2025, ending the year with net leverage around 4.3x and an explicit goal of bringing that metric below 4.0x by the end of 2026.

Balance Sheet First: Dividend Reset and R&D Focus

To prioritize balance sheet repair, Organon reduced its dividend payout ratio to free up more cash for debt reduction. It also discontinued certain early-stage clinical programs and tightened R&D spending, aiming capital at marketed and late-stage products that can drive nearer-term returns while tempering long-dated pipeline risk.

Top-Line Softness and Quarterly Volatility

Fourth-quarter revenue fell to $1.57 billion, down about 8% at constant currency, capping a full-year decline of roughly 3%. Management cited about $200 million of LOE-related volume losses and around $180 million of pricing headwinds in 2025, equivalent to roughly a 2.8% drag, illustrating the structural pressures weighing on the portfolio.

Nexplanon Sales Slide Under Policy and Channel Strain

Nexplanon revenue declined approximately 20% ex-FX in Q4 and about 4% for the full year, pressured by U.S. policy-related access limits affecting Planned Parenthood and FQHCs, and by a shift from buy-and-bill to specialty pharmacy channels. The transition to a 5-year label reduced reinsertions, and a roughly $17 million one-time Q4 impact from changes in wholesaler practices, plus added REMS/distribution complexity, create further execution risk.

Respiratory and Atozet: Structural Drags on Established Brands

The respiratory portfolio faced both pricing and volume pressure, including mandatory price cuts in China and rate pressure in the U.S. on Dulera, cutting into established brand performance. Additionally, the loss of exclusivity on Atozet was a roughly 400-basis-point headwind to established brands revenue in 2025, underscoring the challenge of defending mature assets.

Fertility: China Weakness and Rising Competition

While fertility grew for the full year, fourth-quarter fertility sales declined about 6% ex-FX, driven mainly by adverse socioeconomic trends in China that weighed on demand. Management warned that fertility could be a headwind in 2026 as U.S. competition intensifies, including a rival’s agreement tied to a Direct Access Program, heightening market-share risk.

Margins Under Pressure as Mix and Pricing Bite

Non-GAAP adjusted gross margin dropped to 56.7% in Q4 2025 from 60.6% a year earlier, a decline of roughly 390 basis points, and fell to 60.1% for the full year versus 61.6% in 2024. Q4 adjusted EBITDA margin slipped to 25.4% from 28.1%, driven mainly by pricing pressure and less favorable product mix, signaling that cost savings are increasingly being used to offset structural margin erosion.

Goodwill Impairment Highlights Profit and Leverage Strains

Organon posted a GAAP net loss of $205 million in Q4 2025, largely due to a non-cash goodwill impairment of $301 million linked to stock price declines and underperformance in the U.S. market. With net leverage still elevated at about 4.3x and interest expense expected to be high near $500 million in 2026, the balance sheet remains a key risk factor until deleveraging progresses further.

Governance Questions from Unresolved Audit Matters

Management acknowledged an “other matters” item raised with the Audit Committee but declined to offer details, leaving investors with limited visibility on the issue’s scope or implications. Additional references to channel and purchasing issues in the biosimilars business during Q&A further contributed to governance and disclosure uncertainty that could weigh on sentiment.

2026 Guidance: Stability, Modest Growth Drivers and Debt Focus

For 2026, Organon guided to about $6.2 billion in revenue and roughly $1.9 billion in adjusted EBITDA, assuming around $40 million of LOE, $30 million of volume-based pricing impact and about $75 million of price headwinds, offset by roughly $150 million of volume growth and a modest FX tailwind. Management expects gross margin to compress by 75–100 basis points, SG&A to sit in the mid-20% of sales and R&D in the mid-single digits, with free cash flow similar to recent years and net leverage trending below 4.0x by year-end.

Organon’s earnings call painted a narrative of disciplined stabilization rather than acceleration, with strong biosimilars and select growth brands offsetting LOE, pricing and margin pressures. While cost control, cash generation and deleveraging provide support for the equity story, investors will be watching Nexplanon execution, fertility competition and the resolution of audit-related uncertainties to gauge whether stability can eventually transition into sustainable growth.